Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Immucor to increase volume of shares:

This article was originally published in Clinica

Executive Summary

Immucor's existing shareholders are to receive a 50% stock dividend following the company's decision to go ahead with a 3-for-2 stock split. The move will increase the number of shares of common stock outstanding from over 20 million, as recorded at the end of May, to over 30 million. The expected date of distribution is July 16. Since received FDA approval for its fully automated Galileo blood sample analyser in April, the company saw its share price go up nearly 27%. According to the Norcross, Georgia-based company, the aim in increasing the number of shares is to make the price of its stock more accessible to investors of all levels. This is the sixth stock split for Immucor since its IPO in December 1985.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel